AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05533775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Arm A: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of Cycles 2 and 3~Arm B: Participants will receive IV glofitamab on Days 8 and 15 of Cycle 1, then on Day 1 of each cycle thereafter~(Cycle length = 21 days)
Study NCT05533775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive IV rituximab on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
Study NCT05533775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Participants will receive IV ifosfamide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
Study NCT05533775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV carboplatin on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
Study NCT05533775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Participants will receive IV etoposide on Days 3, 4, and 5 of cycle 1 and on Days 5, 6, 7, and 8 of Cycles 2 and 3 (Cycle length = 21 days)
Study NCT05533775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
Study NCT06283719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZG006
Description: ZG006 will be administered as an intravenous (IV) infusion.
Study NCT04908176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablets
Study NCT04908176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam syrup
Study NCT05236114 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study NCT06578156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Cannula
Description: High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
Study NCT06578156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal High Flow Cannula
Description: High flow nasal cannula is a device that provides heated and humidified high flow gases. In-person. Depending on participant's availability, up to 6 times
Study NCT06578156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Low Flow Cannula
Description: Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
Study NCT06578156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Low Flow Cannula
Description: Low flow nasal cannula is a device that provides low flow gases. In-person. Depending on participant's availability, up to 6 times
Study NCT06495450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnidirectional Virtual Reality and Treadmill Training
Description: Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.
Study NCT06495450 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercise
Description: A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
Study NCT04775225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: denervation of the obturator and femoral genicular branches by Lidocaine 2 %
Study NCT04775225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an equivalent amount of saline will be injected subcutaneously in 2 points similar to the active group
Study NCT04775225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: Intra-articular injection of 80mg of triamcinolone
Study NCT04710888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of basil extract gel in treatment of aphthus ulcer
Description: This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
Study NCT04710888 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: muco adhesive placebo gel
Description: mucoadhesive gel without drug which was used as placebo (contains tragacanth gum, alcohol, sodium benzoate, and distilled water) 4 times per day
Study NCT04710888 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: no treatment
Description: (i) had underlying systemic disease(s) or a history of immunologic disorder(s); (ii) were taking immunomodulatory agents or systemic nonsteroidal anti-inflammatory drugs \< 1 month before study commencement; (iii) are smokers; (iv) are pregnant; (v) had a history of abusing drugs or alcohol; (vi) could not provide written informed consent.
Study NCT05145335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoregulated Blood Flow Restriction Cuff (smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training
Description: This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which autoregulates so when the quadriceps muscle contracts, the total amount of pressure doesn't increase, as the tourniquet will lower the pressure to keep the total amount of pressure constant.
Study NCT05145335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-autoregulated blood flow restriction cuff ((smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training)
Description: This group will undergo 2 sessions consisting of a low load leg extension exercise combined with a pressurized tourniquet which does not autoregulate so when the quadriceps muscle contracts, the total amount of pressure will increase, as the tourniquet will not lower the pressure to keep the total amount of pressure constant.
Study NCT06512337 — intervention group
Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label
Study NCT06500676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH375
Description: GFH375 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Study NCT06540768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Normothermia Group
Description: Maintenance of a body temperature between 35 and 37 degrees Celsius using conservative and pharmacological interventions for 72 hours.
Study NCT06540547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MomMA Intervention
Description: Parents will receive sessions of CBT-based behavioral intervention with components targeted specifically towards expectant parents with ADHD. Treatment will be delivered by therapists embedded in OB care settings. The number and specific content of sessions will be determined based on community partner feedback.
Study NCT06607172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral irrigator
Description: water flosser device
Study NCT06607172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oral irrigator
Description: water flosser and 0.075% CPC
Study NCT06607172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetylpyridinium Chloride (CPC)
Description: Cetylpyridinium 0.075%
Study NCT06678945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bar-Clip attachment
Description: The 2 implants will be connected with bar attachments while the denture will be retained over the bar using clip.
Study NCT06678945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bar- OT Equator attachment
Description: The 2 implants will be connected with bar attachments while the denture will be retained over the bar using the OT Equator.
Study NCT06065735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: Paroxetine will be administered
Study NCT06692153 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An AID System.
Description: The embecta Automated Insulin Delivery (AID) System is a closed loop system comprised of 3 components: the embecta insulin pump, a Smartphone with the Tidepool Loop app, and the Dexcom G6 CGM
Study NCT06692153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SC)
Description: Participants will continue to use their current therapy for T2D.
Study NCT06735235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0 ppm F
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT06735235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 250 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT06735235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 1100 ppm as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT06735235 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 2800 ppm F as MFP
Description: Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.
Study NCT06734013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic
Description: RNA will be analysed using a Real-Time PCR expression card (TaqMan Real-Time PCR assay technology - Thermo Fisher Scientific). The analysis will be performed using a Real-Time Light Cycler 480 (Roche). The expression card will be customised for the study, including the genes cxcl9/10, cav-1, rhoj, cdh5, cd96, tnfsf8, il-21r, vcam, klrk1
Study NCT06735170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biologic tuberoplasty
Description: a surgical procedure during which an a cellular dermal allograft is attached to the greater tuberosity to prevent bone-to-bone contact between the greater tuberosity and the acromion with the goal of decreasing pain
Study NCT06735170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subacromial balloon spacer
Description: a biodegradable balloon is inserted into the subacromial space of the shoulder to increase teh distance between the greater tuberosity and the acromion to reduce pain
Study NCT06736119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Oriented Intervention
Description: Intervention group will recieve task oriented interventions.Throwing and catching balls of different sizes and weights will be done. For writing, a task-oriented approach has 4 phases that will involve writing,correcting and fun writing 30-minute per session. Interventions provided 3 days per week for 3 months.
Study NCT06734936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Playing videos with sgg
Description: Playing videos with sgg
Study NCT05433168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SHIATSU
Description: The patients will benefit from shiatsu treatments by a professional according to the shiatsu protocol developed by the Syndicate's evaluation commission Shiatsu Professionals (SPS).
Study NCT05433168 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DUMMY SHIATSU
Description: Exercising a fake shiatsu is a real problem as opinions differ. The consensus of the different schools and styles of the technique is that shiatsu pressure is weight transfer. We are therefore going to remove this aspect from the SFASPA shiatsu protocol. The professional will run the same sequence of points, without any weight transfer, being only in contact with the receiver
Study NCT04651010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal MRI
Description: Multimodal MRI will be realized between 12 and 24 hours after thrombectomy
Study NCT05653440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accuracy-maximized condition
Description: Naming treatment condition in which the target will be immediately provided for repetition at picture onset.
Study NCT05653440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effort-maximized condition
Description: Naming treatment condition in which participants will have up to 10 seconds to respond before the target is provided for repetition.
Study NCT05653440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effort-accuracy balanced condition
Description: Naming treatment condition in which naming deadlines will be determined based on the balanced effort-to-accuracy benefit ratio formalized above, calculated on clinician-provided accuracy and response time ratings. Deadlines will be recalculated session-by-session to adjust to participant-specific treatment gains over time.
Study NCT05484570 — intervention group
Intervention type: OTHER
Intervention: Interval History
Description: The study coordinator or another team member will review standard health questions relevant to DNA repair disorders. The control group will not undergo an interval history. These questions will include:~1. How the participant's appetite and general weight trajectory has been since the last assessment~2. Any episodes of unexplained bleeding or bruising~3. Any jaundice~4. General level of alertness and interaction with family and others~5. Any changes in cognitive function such as speech, following commands, comprehension~6. Any changes in motor function, including the development of tremors and stiffness in movements
Study NCT05484570 — intervention group
Intervention type: OTHER
Intervention: Physical Examination
Description: A board-certified neurologist (the principal investigator) will perform a general physical examination and a neurological examination and complete a standard CRF to document relevant findings. The control group will not undergo a physical examination.
Study NCT05484570 — intervention group
Intervention type: OTHER
Intervention: ECAB Assessment
Description: An Early Clinical Assessment of Balance (ECAB) will be performed by the physical therapist. Part I can be assessed in all affected individuals, and Part II requires ambulation. For non-ambulatory individuals, only Part I will be applied. The items in the ECAB are summarized as follows:~Part I. Head and trunk postural control (maximum 36 points) Head righting - lateral (right and left) Head righting - extension Head righting - flexion Rotation in trunk (right and left) Equilibrium reactions in sitting (right and left) Protective extension - side Protection extension - backward Part II. Sitting and standing postural control (maximum 64 points) Sitting with back unsupported but feet supported on floor or on a stool Sitting to standing Standing unsupported with eyes closed Standing unsupported with feet together Turns 360 degrees Placing alternate foot on the step while standing unsupported
Study NCT05484570 — intervention group
Intervention type: OTHER
Intervention: Gait Assessment
Description: For ambulatory participants, the physical therapist will also assess standardized gait outcome measures, including:~1. Gait Speed: may be measured over a 10 meter distance, assessing both comfortable walking speed and fast walking speed~2. 10-meter walk/run: timed assessment at fastest gait attainable. This assessment would be omitted for those participants who are determined to have a high fall risk.~3. Timed Up and Go (TUG): time to stand from a chair, walk 3 meters, go around a cone, and return to the chair (with or without an assistive device)~4. Dynamic Gait Index (DGI): assesses 8 balance challenges while walking
Study NCT05484570 — intervention group
Intervention type: OTHER
Intervention: Specimen Sample Collection
Description: Total blood volumes collected at each visit will be limited to 5mL/kg body weight, with a maximum of 18mL.~Saliva samples may be obtained if research is taking place where blood samples cannot be drawn or transferred.
Study NCT06318897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV
Study NCT06318897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV
Study NCT06318897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV
Study NCT06318897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given by IV
Study NCT06318897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV
Study NCT05683171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV (vein)
Study NCT05683171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by PO
Study NCT05683171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valemetostat
Description: Given by PO
Study NCT05548452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intestinal Microbiota Transplant (IMT) Capsules
Description: Capsules containing freeze-dried intestinal microbiota from healthy human donors
Study NCT05548452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Capsules containing an inactive substance (sugar pill)
Study NCT06291285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine-THU
Description: Orally administered immediate release tablets.
Study NCT06291285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine-THU
Description: Orally administered delayed release capsules.
Study NCT05591274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmileyScope Virtual Reality Headset
Description: The SmileyScope Virtual Reality Headset is a VR headset undergoing study for approval by the U.S. Food and Drug Administration (FDA) to reduce pain and anxiety in patients aged 4 years and older undergoing needle blood draw or injection procedures. Currently, this device has been granted entrance to the FDA Safer Technologies Program. The device comes pre-loaded with either an interactive or static virtual reality scenario.
Study NCT03986086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH966
Description: RP2D tablet
Study NCT03986086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MPH966 placebo table
Study NCT05973617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of corneal biomechanical properties
Description: Measurement of corneal biomechanics
Study NCT04968197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestibular Intervention via Portable Electrical Stimulator (VIPES) system
Description: A small, lightweight device able to deliver stochastic vestibular stimulation (SVS) using a comfortable electrode set on the back of the head as well as other proven modes of galvanic vestibular stimulation (GVS) related vestibular correction when required to mitigate motion sickness or provide auxiliary vestibular cueing.
Study NCT05137496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 0.3mg/kg/d, iv.gtt, for at least 2 weeks
Study NCT05137496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 2mg/kg, d1-d5, gradually reduced, for at least 2 weeks
Study NCT04703478 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise
Description: Participants will carry out a breathing exercise program through the RespiraConNosotros mobile application. They will be asked to carry out the proposed exercises with a frequency of 3 times a week for 3 months.
Study NCT04946903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2007
Description: Take it once per period.
Study NCT04946903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2008
Description: Take it once per period.
Study NCT04946903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1902
Description: Take it once per period.
Study NCT04624880 — intervention group
Intervention type: DEVICE
Intervention: Giant magnetoresistive sensor (GMR)
Description: Giant magnetoresistive sensor analyzes genetic polymorphisms in patient samples.
Study NCT04293406 — intervention group
Intervention type: OTHER
Intervention: Decision Navigation Intervention (DNI)
Description: This study will develop and test the acceptability and feasibility of a decision navigation intervention (DNI) for AA or H/L men with prostate cancer through consideration of the role of partners and family members in the decision-making process. In the decision navigation intervention (DNI), participants will meet with the navigator in person or via phone, prior to their specialist treatment consultation. At the end of the DNI visit, participants will receive a personalized list of prioritized questions. At the end of the decision navigation appointment, all navigated patients will complete a five-item navigation rating scale evaluating the intervention and its impact on their preparation for the consultation visit.
Study NCT06233136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg pedalling exercise
Description: Each child in the experimental group will be positioned in inclined position and will cycle through the range of motion under the supervision of the researcher
Study NCT06233136 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The designed physical therapy program
Description: It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises
Study NCT06233136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The designed physical therapy program
Description: It applied for all participated children in both groups. It includes;~1. Flexibility exercises~2. Static and dynamic balance~3. Functional training exercises
Study NCT01725516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release technique